- Home
- MMD vs ATAI Comparison
MMD vs ATAI Comparison
Compare MMD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMD
- ATAI
- Stock Information
- Founded
- MMD 2012
- ATAI 2018
- Country
- MMD United States
- ATAI Germany
- Employees
- MMD N/A
- ATAI N/A
- Industry
- MMD Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- MMD Finance
- ATAI Health Care
- Exchange
- MMD Nasdaq
- ATAI Nasdaq
- Market Cap
- MMD 268.0M
- ATAI 282.6M
- IPO Year
- MMD N/A
- ATAI 2021
- Fundamental
- Price
- MMD $14.18
- ATAI $1.47
- Analyst Decision
- MMD
- ATAI Strong Buy
- Analyst Count
- MMD 0
- ATAI 3
- Target Price
- MMD N/A
- ATAI $10.50
- AVG Volume (30 Days)
- MMD 74.7K
- ATAI 1.8M
- Earning Date
- MMD 01-01-0001
- ATAI 05-14-2025
- Dividend Yield
- MMD 4.88%
- ATAI N/A
- EPS Growth
- MMD N/A
- ATAI N/A
- EPS
- MMD N/A
- ATAI N/A
- Revenue
- MMD N/A
- ATAI $308,000.00
- Revenue This Year
- MMD N/A
- ATAI $65.58
- Revenue Next Year
- MMD N/A
- ATAI N/A
- P/E Ratio
- MMD N/A
- ATAI N/A
- Revenue Growth
- MMD N/A
- ATAI N/A
- 52 Week Low
- MMD $14.30
- ATAI $1.03
- 52 Week High
- MMD $17.67
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- MMD 34.91
- ATAI 52.18
- Support Level
- MMD $14.00
- ATAI $1.41
- Resistance Level
- MMD $14.51
- ATAI $1.51
- Average True Range (ATR)
- MMD 0.25
- ATAI 0.12
- MACD
- MMD -0.03
- ATAI 0.03
- Stochastic Oscillator
- MMD 15.43
- ATAI 87.50
About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
MainStay MacKay DefinedTerm Municipal Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.